cbdMD, Inc.: directors' dealings · United States · SEC (Form 4)

About cbdMD, Inc.

cbdMD, Inc. (ticker: YCBD) is listed in the United States on NYSE American, a NYSE market segment typically associated with small-cap equities. For international investors, it is best understood as a consumer wellness / cannabinoid exposure to the U.S. hemp market rather than a traditional pharmaceutical company. The company is organized as a North Carolina corporation and operates from Charlotte, North Carolina, where its principal offices are located. Its origins date back to 2015, when it was formed as Level Beauty Group, Inc.; the company later became Level Brands, Inc. and adopted the cbdMD name in 2019. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644903/000143774925038435/ycbd20250930_10k.htm?utm_source=openai)) cbdMD’s business model centers on the development, marketing, and distribution of hemp-derived wellness products. The core cbdMD brand spans a broad assortment of consumer products, including CBD tinctures, gummies, topicals, capsules, bath bombs, sleep aids, drink mixes, and Farm Bill-compliant Delta-9 products. The company also emphasizes THC-free and Full Spectrum offerings, along with NSF Certified for Sport® products, which helps it target health-conscious consumers and athletes who care about compliance and product quality. In addition to the flagship brand, cbdMD operates Paw CBD, a pet-focused line, and ATRx, a natural functional mushroom support brand. ([investors.cbdmd.com](https://investors.cbdmd.com/?utm_source=openai)) From a competitive perspective, cbdMD operates in a crowded and highly regulated category, where brand trust, product consistency, distribution reach, and regulatory compliance matter as much as product formulation. The company says its products are sold through e-commerce and through thousands of retail outlets across the United States, giving it a hybrid direct-to-consumer and wholesale footprint. That model provides brand visibility and channel diversification, but it also leaves the business exposed to pricing pressure and changing federal hemp rules. Recent filings and company commentary also highlight regulatory uncertainty around hemp-derived THC products, which remains one of the key strategic risks for the sector. ([investors.cbdmd.com](https://investors.cbdmd.com/?utm_source=openai)) Recent developments have been more constructive at the operating level. In May 2026, cbdMD reported year-over-year and sequential revenue growth, pointing to the integration of Bluebird Botanicals and broader commercial momentum. Earlier updates also referred to improving liquidity and a trend toward profitability, although management continued to warn about going-concern risk and the possibility that new hemp legislation could materially affect the business. The stock therefore remains a speculative U.S. small-cap cannabis/wellness name: potentially interesting for investors seeking asymmetric upside, but still dependent on execution, acquisitions, and the direction of U.S. federal hemp regulation. ([prnewswire.com](https://www.prnewswire.com/news-releases/cbdmd-reports-19-year-over-year-and-12-sequential-revenue-growth-bluebird-acquisition-integration-and-medicare-bei-pathway-position-company-for-continued-momentum-302772723.html?utm_source=openai))